Samantha E. Bowyer
Hospital Avenue
Nedlands, WA 6009, Australia
Nedlands, WA 6009, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 25, 2026
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 29, 2025
Geriatric assessment practices in oncology: A survey of Australian clinicians.
Journal: Journal of geriatric oncology
Published: September 29, 2025
Prolonged Survival in Anaplastic Thyroid Cancer: Insights From Multi-Modal Treatment.
Journal: Asia-Pacific journal of clinical oncology
Published: September 01, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 09, 2025
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study.
Journal: Journal of the American Academy of Dermatology
Published: June 19, 2025
Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA).
Journal: JTO clinical and research reports
Published: June 06, 2025
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Journal: The New England journal of medicine
Published: June 02, 2025
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 01, 2025
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: February 14, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Journal: Journal of the American Academy of Dermatology
Published: January 05, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 02, 2024
Last Updated: 09/26/2026